Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Arya Sciences Acquisition Corp III Cl A (ARYA)

Arya Sciences Acquisition Corp III Cl A (ARYA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 186,483
  • Shares Outstanding, K 16,710
  • Annual Sales, $ 0 K
  • Annual Income, $ -520 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow 105.55
  • Price/Book 54.44
Trade ARYA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 08/10/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.07
  • Growth Rate Est. (year over year) +1,427,042.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.83 +13.53%
on 05/11/21
11.25 -0.81%
on 06/09/21
+1.11 (+11.04%)
since 05/07/21
3-Month
9.82 +13.65%
on 05/07/21
15.00 -25.60%
on 03/16/21
-1.99 (-15.13%)
since 03/09/21

Most Recent Stories

More News
Nautilus Biotechnology Debuts as Publicly Traded Company, Seeks to Deliver on the Untapped Potential of the Human Proteome

SEATTLE and NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the...

ARYA : 11.16 (+4.49%)
ARYA Sciences Acquisition Corp III Announces Extraordinary General Meeting Teleconference Details

NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp III (“ARYA”) (Nasdaq: ARYA), today announced that, due to the public health and safety concerns related to the coronavirus...

ARYA : 11.16 (+4.49%)
Nautilus Biotechnology Appoints Matt Murphy as General Counsel

Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, today announced the appointment of Matt Murphy, Esq., as General Counsel....

ARYA : 11.16 (+4.49%)
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of ARYA Sciences Acquisition Corp III Merger

WILMINGTON, Del., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating ARYA Sciences Corp III (“ARYA”) (NASDAQ CM: ARYA ) regarding possible breaches of fiduciary...

ARYA : 11.16 (+4.49%)
Next-Gen Proteomics Company Nautilus Biotechnology to List on Nasdaq Through Merger with Arya Sciences Acquisition Corp III

Nautilus Biotechnology, Inc. ("Nautilus Biotechnology" or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, and Arya Sciences Acquisition...

ARYA : 11.16 (+4.49%)
Immatics Announces Completion of Business Combination and Listing on NASDAQ

Houston, Texas and Tuebingen, Germany, July 02, 2020 (GLOBE NEWSWIRE) --

ARYA : 11.16 (+4.49%)
Arya Sciences Acquisition Corp. Shareholders Approve Business Combination Transaction with Immatics

Arya Sciences Acquisition Corp. (NASDAQ: ARYA or “Arya”), a special purpose acquisition company sponsored by Perceptive Advisors, and Immatics Biotechnologies GmbH (“Immatics”), a clinical-stage...

ARYA : 11.16 (+4.49%)
ARYA Sciences Acquisition Corp. Announces Annual General Meeting Teleconference Details

New York, NY, June 22, 2020 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp. (“ARYA” or “the Company”) (NASDAQ: ARYA), today announced that, due to the public health and safety concerns...

ARYBU : 10.39 (-1.05%)
ARYA : 11.16 (+4.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Arya Sciences Acquisition Corp. is a blank check company. It formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. Arya Sciences Acquisition Corp. is based in New York, United...

See More

Key Turning Points

3rd Resistance Point 11.83
2nd Resistance Point 11.54
1st Resistance Point 11.35
Last Price 11.16
1st Support Level 10.87
2nd Support Level 10.58
3rd Support Level 10.39

See More

52-Week High 25.89
Fibonacci 61.8% 19.75
Fibonacci 50% 17.85
Fibonacci 38.2% 15.96
Last Price 11.16
52-Week Low 9.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar